目的：评价利妥昔单克隆抗体联合CHOP方案治疗高龄非霍奇金淋巴瘤（ NHL）患者的疗效。方法将2010年10月至2013年10月入院的76例老年NHL患者随机分为两组；CHOP方案组36例，利妥昔单克隆抗体联合 CHOP 方案组40例。采用回顾分析方法，比较两组患者6个疗程后的临床疗效并记录其不良反应。结果 CHOP组患者的完全缓解率为25.00％，总有效率为55.56％；利妥昔单克隆抗体联合 CHOP方案组分别为45.00％，77.50％，两组总有效率差异具有统计学意义（χ2＝4.133，P＜0.05）；两组治疗方案毒副反应发生率差异无统计学意义（ P＞0.05）；两组治疗前的IgA、lgG、IgM 水平均无统计学差异（ P＞0.05），治疗后水平均较治疗前显著下降（ P＜0.05），且两组间无统计学差异（ P＞0.05）。结论利妥昔单克隆抗体联合CHOP方案治疗高龄NHL临床疗效较好且不良反应未增加，但还应实时监测患者的免疫功能。%Objective To evaluate the clinical effect of Rituximab combined with CHOP scheme in the treatment of elderly patients with non Hodgkin's lymphoma ( NHL) .Methods Methods:76 cases of elderly patients with NHL from October 2010 to October 2013 were randomly divided into two groups:36 cases of CHOP group ,40 cases of Rituximab combined with CHOP scheme group .The clinical curative effect of two groups were compared after 6 courses of treatment and the adverse reaction was recorded .Results The complete remission rate of CHOP group was 25%, and the total effective rate was 55 .56%;while the complete remission rate in Rituximab combined with CHOP scheme group was 45.00%,and the total effective rate was 77.50%,the total effective rate between two groups had statistically significant difference(χ2=4.133,P=0.042).The treatment adverse reaction rate between two groups had no significant difference (P>0.05 ).There were no statistical differences of IgA , IgG, IgM levels between the two groups before treatment (P>0.05), and they were higher than those before treatment (P<0.05), but there were no significant differences between the two groups after treatment (P>0.05).Conclusions The clinical effect of Rituximab combined with CHOP scheme in the treatment of elderlypatients with NHL is good and adverse reactions do not in -crease.
展开▼
